Simulations Plus, Inc.

  • Market Cap: Micro Cap
  • Industry: Software Products
  • ISIN: US8292141053
USD
14.14
-1.26 (-8.18%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

330.39 k

Shareholding (Nov 2025)

FII

14.68%

Held by 83 FIIs

DII

37.69%

Held by 49 DIIs

Promoter

1.76%

How big is Simulations Plus, Inc.?

22-Jun-2025

As of Jun 18, Simulations Plus, Inc. has a market capitalization of 368.43 million, with net sales of 78.55 million and a net profit of 7.26 million over the latest four quarters. The balance sheet as of Aug 24 shows shareholder's funds of 182.43 million and total assets of 207.64 million.

As of Jun 18, Simulations Plus, Inc. has a market capitalization of 368.43 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 78.55 million and a net profit of 7.26 million for the latest four quarters.<BR><BR>As of Aug 24, the balance sheet shows shareholder's funds of 182.43 million and total assets of 207.64 million.

View full answer

What does Simulations Plus, Inc. do?

22-Jun-2025

Simulations Plus, Inc. develops software for drug discovery and development, with recent net sales of $22 million and a net profit of $3 million. The company has a market cap of $368.43 million and key metrics include a P/E ratio of 107.00 and a dividend yield of 0.32%.

Overview:<BR>Simulations Plus, Inc. is a developer of drug discovery and development software, operating within the Software Products industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 22 Million (Quarterly Results - Feb 2025)<BR>- Most recent Net Profit: 3 Million (Quarterly Results - Feb 2025)<BR>- Market-cap: USD 368.43 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 107.00<BR>- Dividend Yield: 0.32%<BR>- Debt Equity: -0.11<BR>- Return on Equity: 2.74%<BR>- Price to Book: 1.94<BR><BR>Contact Details:<BR>- Address: 42505 10th St W, LANCASTER CA: 93534-7059<BR>- Tel: 1 661 7237723<BR>- Fax: 1 661 7235524<BR>- Website: https://www.simulations-plus.com/

View full answer

Should I buy, sell or hold Simulations Plus, Inc.?

22-Jun-2025

Who are in the management team of Simulations Plus, Inc.?

22-Jun-2025

As of March 2022, the management team of Simulations Plus, Inc. includes Chairman Walter Woltosz and independent directors Dr. Lisa LaVange, Dr. John Paglia, Dr. David Ralph, and Dr. Daniel Weiner.

As of March 2022, the management team of Simulations Plus, Inc. includes Mr. Walter Woltosz, who serves as the Chairman of the Board. Additionally, the board features several independent directors: Dr. Lisa LaVange, Dr. John Paglia, Dr. David Ralph, and Dr. Daniel Weiner.

View full answer

Is Simulations Plus, Inc. overvalued or undervalued?

20-Sep-2025

As of July 14, 2025, Simulations Plus, Inc. is considered risky and overvalued, with a high P/E ratio of 107 and poor stock performance, reflected in a year-to-date return of -43.13%, compared to the S&P 500's 12.22%.

As of 14 July 2025, the valuation grade for Simulations Plus, Inc. has moved from very expensive to risky, indicating a shift in perception regarding its market value. The company appears to be overvalued, as evidenced by a P/E ratio of 107, which significantly exceeds the peer average, and an EV to EBITDA ratio of 44.51, suggesting that investors are paying a premium for earnings before interest, taxes, depreciation, and amortization. Additionally, the Price to Book Value stands at 2.92, further highlighting the disparity between the company's market price and its book value.<BR><BR>In comparison to its peers, Simulations Plus, Inc. has a P/E ratio of 22.90, while Everbridge, Inc. shows a negative P/E of -28.60, and Definitive Healthcare Corp. has a P/E of 8.68, indicating that Simulations Plus is trading at a higher valuation despite its underperformance. The company's recent stock performance has been poor, with a year-to-date return of -43.13%, significantly lagging behind the S&P 500's return of 12.22% in the same period, which reinforces the notion of overvaluation.

View full answer

Is Simulations Plus, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Simulations Plus, Inc. shows a mildly bearish trend influenced by daily moving averages and KST, despite a mildly bullish weekly MACD, while significantly underperforming the S&P 500 with a year-to-date return of -43.13%.

As of 11 September 2025, the technical trend for Simulations Plus, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the KST, which are both bearish. The weekly MACD indicates a mildly bullish signal, but this is offset by the monthly bearish indicators in MACD, Bollinger Bands, and KST. The Dow Theory shows a mildly bullish stance on the weekly timeframe but remains bearish monthly. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -43.13% versus the S&P 500's 12.22%, and a one-year return of -49.57% compared to the S&P 500's 17.14%.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

The company has declared Negative results for the last 3 consecutive quarters

  • OPERATING CASH FLOW(Y) Lowest at USD 14.2 MM
  • ROCE(HY) Lowest at -41.49%
  • DIVIDEND PAYOUT RATIO(Y) Lowest at 0%
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Software Products

stock-summary
Market cap

USD 411 Million (Micro Cap)

stock-summary
P/E

107.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

9.83%

stock-summary
Price to Book

3.23

Revenue and Profits:
Net Sales:
18 Million
(Quarterly Results - Nov 2025)
Net Profit:
1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.82%
0%
-16.82%
6 Months
8.85%
0%
8.85%
1 Year
-60.17%
0%
-60.17%
2 Years
-62.65%
0%
-62.65%
3 Years
-66.88%
0%
-66.88%
4 Years
-65.16%
0%
-65.16%
5 Years
-83.21%
0%
-83.21%

Simulations Plus, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
14.94%
EBIT Growth (5y)
-14.85%
EBIT to Interest (avg)
9.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.45
Tax Ratio
8.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
18.53%
ROE (avg)
7.23%

Valuation key factors

Factor
Value
P/E Ratio
107
Industry P/E
Price to Book Value
2.92
EV to EBIT
134.36
EV to EBITDA
44.51
EV to Capital Employed
3.16
EV to Sales
6.78
PEG Ratio
NA
Dividend Yield
0.22%
ROCE (Latest)
2.35%
ROE (Latest)
2.74%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Nov 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 56 Schemes (45.81%)

Foreign Institutions

Held by 83 Foreign Institutions (14.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Nov 2025 is 5.14% vs -14.22% in Aug 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Nov 2025 is 200.00% vs 98.96% in Aug 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Nov'25",
        "Aug'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.40",
          "val2": "17.50",
          "chgp": "5.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.10",
          "val2": "2.00",
          "chgp": "5.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.70",
          "val2": "-0.70",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.70%",
          "val2": "37.70%",
          "chgp": "0.10%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Aug'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Aug 2025 is 13.14% vs 17.45% in Aug 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Aug 2025 is -747.00% vs 0.00% in Aug 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Aug'25",
        "Aug'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "79.20",
          "val2": "70.00",
          "chgp": "13.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "14.80",
          "val2": "11.80",
          "chgp": "25.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-76.70",
          "val2": "1.60",
          "chgp": "-4,893.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-64.70",
          "val2": "10.00",
          "chgp": "-747.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "83.30%",
          "val2": "87.60%",
          "chgp": "-0.43%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Nov'25 - QoQstock-summary

Nov'25
Aug'25
Change(%)
Net Sales
18.40
17.50
5.14%
Operating Profit (PBDIT) excl Other Income
2.10
2.00
5.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.70
-0.70
200.00%
Operating Profit Margin (Excl OI)
38.70%
37.70%
0.10%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Nov 2025 is 5.14% vs -14.22% in Aug 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Nov 2025 is 200.00% vs 98.96% in Aug 2025

Annual Results Snapshot (Consolidated) - Aug'25stock-summary

Aug'25
Aug'24
Change(%)
Net Sales
79.20
70.00
13.14%
Operating Profit (PBDIT) excl Other Income
14.80
11.80
25.42%
Interest
0.00
0.00
Exceptional Items
-76.70
1.60
-4,893.75%
Consolidate Net Profit
-64.70
10.00
-747.00%
Operating Profit Margin (Excl OI)
83.30%
87.60%
-0.43%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Aug 2025 is 13.14% vs 17.45% in Aug 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Aug 2025 is -747.00% vs 0.00% in Aug 2024

stock-summaryCompany CV
About Simulations Plus, Inc. stock-summary
stock-summary
Simulations Plus, Inc.
Software Products
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.
Company Coordinates stock-summary
Company Details
42505 10th St W , LANCASTER CA : 93534-7059
stock-summary
Tel: 1 661 72377231 661 7237723
stock-summary
Registrar Details